Literature DB >> 14871806

Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.

Sylvia S W Ng1, William D Figg, Alex Sparreboom.   

Abstract

Paclitaxel (Taxol) and docetaxel (Taxotere) have been shown to inhibit angiogenesis at low concentrations that do not affect cancer cell proliferation. Here, we used rat aortic rings and human umbilical vein endothelial cells to evaluate the influence of their formulation vehicles Cremophor EL and polysorbate 80, as well as serum binding proteins on taxane-mediated antiangiogenesis. The data show that clinically relevant concentrations of the vehicles and binding proteins nullify the antiangiogenic activity of both taxanes. It is suggested that these agents may need to be used at much higher doses than anticipated for effective antiangiogenic chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871806     DOI: 10.1158/0008-5472.can-03-3391

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivo.

Authors:  Yue Huang; Xiao-Mei Chen; Bing-Xiang Zhao; Xi-Yu Ke; Bo-Jun Zhao; Xin Zhao; Ying Wang; Xuan Zhang; Qiang Zhang
Journal:  AAPS PharmSciTech       Date:  2010-05-05       Impact factor: 3.246

2.  Remodeling Characteristics and Collagen Distributions of Biologic Scaffold Materials Biopsied From Postmastectomy Breast Reconstruction Sites.

Authors:  Jaime A Cavallo; Noopur Gangopadhyay; Jason Dudas; Andres A Roma; Mateusz S Jasielec; Jack Baty; Sara Baalman; Margaret M Frisella; Marissa M Tenenbaum; Terence M Myckatyn; Brent D Matthews; Corey R Deeken
Journal:  Ann Plast Surg       Date:  2015-07       Impact factor: 1.539

3.  Polymeric micelles for the pH-dependent controlled, continuous low dose release of paclitaxel.

Authors:  Adam W G Alani; Younsoo Bae; Deepa A Rao; Glen S Kwon
Journal:  Biomaterials       Date:  2009-12-03       Impact factor: 12.479

4.  Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

Authors:  Domingo G Perez; Vera J Suman; Tom R Fitch; Thomas Amatruda; Roscoe F Morton; Shamim Z Jilani; Costas L Constantinou; James R Egner; Lisa A Kottschade; Svetomir N Markovic
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

5.  Highly selective and sensitive assay for paclitaxel accumulation by tumor cells based on selective solid phase extraction and micro-flow liquid chromatography coupled to mass spectrometry.

Authors:  Julio R Gaspar; Jun Qu; Ninfa L Straubinger; Robert M Straubinger
Journal:  Analyst       Date:  2008-10-03       Impact factor: 4.616

6.  Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters.

Authors:  Elena A Dubikovskaya; Steve H Thorne; Thomas H Pillow; Christopher H Contag; Paul A Wender
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-19       Impact factor: 11.205

7.  Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.

Authors:  Natsuko Onishi; Wen Li; David C Newitt; Roy J Harnish; Fredrik Strand; Alex Anh-Tu Nguyen; Vignesh Amal Arasu; Jessica Gibbs; Ella F Jones; Lisa J Wilmes; John Kornak; Bonnie N Joe; Elissa R Price; Haydee Ojeda-Fournier; Mohammad Eghtedari; Kathryn W Zamora; Stefanie Woodard; Heidi R Umphrey; Michael T Nelson; An L Church; Patrick J Bolan; Theresa Kuritza; Kathleen Ward; Kevin Morley; Dulcy Wolverton; Kelly Fountain; Dan Lopez Paniagua; Lara Hardesty; Kathleen R Brandt; Elizabeth S McDonald; Mark Rosen; Despina Kontos; Hiroyuki Abe; Deepa Sheth; Erin Crane; Charlotte Dillis; Pulin Sheth; Linda Hovanessian-Larsen; Dae Hee Bang; Bruce Porter; Karen Y Oh; Neda Jafarian; Luminita A Tudorica; Bethany Niell; Jennifer Drukteinis; Mary S Newell; Marina E Giurescu; Elise Berman; Constance D Lehman; Savannah C Partridge; Kimberly A Fitzpatrick; Marisa H Borders; Wei Tse Yang; Basak Dogan; Sally Hayward Goudreau; Thomas Chenevert; Christina Yau; Angela DeMichele; Donald A Berry; Laura J Esserman; Nola M Hylton
Journal:  Radiology       Date:  2021-08-24       Impact factor: 29.146

8.  Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor.

Authors:  J-C Tseng; T Granot; V DiGiacomo; B Levin; D Meruelo
Journal:  Cancer Gene Ther       Date:  2009-10-02       Impact factor: 5.987

9.  Paclitaxel-loaded polymeric nanoparticles based on α-tocopheryl succinate for the treatment of head and neck squamous cell carcinoma: in vivo murine model.

Authors:  Juan Riestra-Ayora; Carolina Sánchez-Rodríguez; Raquel Palao-Suay; Joaquín Yanes-Díaz; Ana Martín-Hita; María Rosa Aguilar; Ricardo Sanz-Fernández
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

Review 10.  The pharmacological bases of the antiangiogenic activity of paclitaxel.

Authors:  Guido Bocci; Antonello Di Paolo; Romano Danesi
Journal:  Angiogenesis       Date:  2013-02-07       Impact factor: 9.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.